C07K 2317/72
Increased effector function due to an fc-modification
Official title: Increased effector function due to an Fc-modification
C07K2317/72 (Increased effector function due to an fc-modification) appears on 615 US grants and 1,402 published applications in this corpus.
Search patents in C07K- Granted patents
- 615
- Published applications
- 1,402
- Assignees
- 426
- Inventors
- 2,438
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 0 | 1 |
| 2002 | 0 | 0 |
| 2003 | 1 | 1 |
| 2004 | 0 | 4 |
| 2005 | 0 | 4 |
| 2006 | 0 | 13 |
| 2007 | 2 | 35 |
| 2008 | 4 | 37 |
| 2009 | 2 | 37 |
| 2010 | 12 | 41 |
| 2011 | 14 | 32 |
| 2012 | 15 | 41 |
| 2013 | 23 | 43 |
| 2014 | 26 | 64 |
| 2015 | 35 | 57 |
| 2016 | 19 | 55 |
| 2017 | 40 | 63 |
| 2018 | 34 | 72 |
| 2019 | 49 | 81 |
| 2020 | 44 | 88 |
| 2021 | 50 | 103 |
| 2022 | 55 | 103 |
| 2023 | 40 | 82 |
| 2024 | 46 | 126 |
| 2025 | 63 | 130 |
| 2026 | 41 | 89 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for treating cancer6 Oct 2026US 12,753,236 B2Alpha Beta Holdings, LLC
- Monoclonal antibodies against CLDN18.2 and Fc-engineered versions thereof15 Sep 2026US 12,735,479 B2Shijiazhuang Yiling Pharmaceutical Co., Ltd.
- Modification of antibody FcRn binding1 Sep 2026US 12,723,069 B2Hoffmann-La Roche Inc.
- Anti-hemojuvelin (HJV) antibodies for treating myelofibrosis25 Aug 2026US 12,715,916 B2AbbVie Deutschland GmbH & Co. KG
- Methods of using anti-hemojuvelin (HJV) antibodies for treating myelofibrosis25 Aug 2026US 12,715,917 B2Abb Vie Inc.
- Methods of treating colorectal cancer using a combination of a ctla-4 inhibitor and a pd-1 inhibitor8 Oct 2026US 2026/0308257 A1Agenus Inc.
- Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators10 Sep 2026US 2026/0265414 A1Yale University
- Antibody against hepatitis b virus, preparation thereof and use thereof27 Aug 2026US 2026/0250361 A1Huahui Health Ltd.
- Methods for treating igg4-related diseases27 Aug 2026US 2026/0250393 A1Xencor, Inc.
- Method of depleting target antigen-specific antibody from a patient by administering a fusion protein (seldeg) for selectively depleting antigen-specific antibodies27 Aug 2026US 2026/0250407 A1The Texas A&M University System
Most cited
By later US patents
- Polypeptide variants521US 6,528,624 B1Genentech, Inc. · 2003
- Optimized Fc variants463US 7,317,091 B2Xencor, Inc. · 2008
- Identification and engineering of antibodies with variant Fc regions and methods of using same227US 7,355,008 B2MacroGenics, Inc. · 2008
- Optimized Fc variants and methods for their generation218US 7,662,925 B2Xencor, Inc. · 2010
- Engineering Fc Antibody regions to confer effector function158US 7,632,497 B2MacroGenics, Inc. · 2009